Novel 5-HT2C agonists demonstrate potential for treating personality and eating disorders, suggesting new therapeutic avenues.
Provided herein are novel 5,6-dihydro-4H-pyrrolo-[3,2,1-ij]-quinoline-5-yl amine compounds as 5-HT2C agonists, pharmaceutical compositions, use of such compounds in treating psychotic disorders, namely, personality disorders and eating disorders, and processes for preparing such compounds.
No takes yet. Share an insight, caveat, or question.
Ram W. Sabnis (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: